Resolution of rheumatoid arthritis symptoms with imatinib mesylate

Journal of Clinical Rheumatology

Volumn 15, Issue 5, 2009, Pages 267-

  Vernon, Matthew R ^a   Pearson, Larry ^b   Atallah, Ehab ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b West Suburban Center for Arthritis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; GOLD; HYDROXYCHLOROQUINE; IMATINIB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROCHLORPERAZINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAND; HUMAN; HYPERVOLEMIA; LETTER; LEUKEMIA REMISSION; MORNING STIFFNESS; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SWELLING; SYNOVITIS; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 69549097990     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181b0d352     Document Type: Letter

References (10)

1. Eklund KK, Lindstedt K, Sandler C, et al. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol. 2008;14:294-296.
2. Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006;116:2633-2642. (Pubitemid 44511627)
3. Eklund KK, Remitz A, Kautiainen H, et al. Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology (Oxford). 2006;45:1573-1575. (Pubitemid 44817070)
4. Ando W, Hashimoto J, Nampei A, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab. 2006;24:274-282. (Pubitemid 43992670)
5. Koyama K, Hatsushika K, Ando T, et al. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol. 2007;17:306-310. (Pubitemid 47263822)
6. Ceponis A, Konttinen YT, Takagi M, et al. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol. 1998;25:2304-2314. (Pubitemid 28551844)
7. Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev. 2007;217:38-52.
8. Juurikivi A, Sandler C, Lindstedt KA, et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis. 2005;64:1126-1131. (Pubitemid 41113344)
9. Dewar AL, Zannettino AC, Hughes TP, et al. Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005;4:851-853.
10. Sandler C, Joutsiniemi S, Lindstedt KA, et al. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2006;347:31-35. (Pubitemid 44015645)